Value-based healthcare: How to harness patient-reported outcomes for better cancer care
12 April 2022 - CHES Policy Dialogue
Speakers: Adela Maghear, Senior EU Affairs Officer, European Cancer Patient Coalition; Christina R. Åkerman, Chair of The 5612 Group AB; Senior Institute Associate at the Institute for Strategy and Competitiveness, Harvard Business School; Claire Chabloz, Medical Director, Johnson & Johnson Medical Devices France; Giovanni Gorgoni, Chair, European Regional and Local Health Authorities; Hans Martens, Senior Adviser, European Policy Centre; Jan De Maeseneer, Professor, Department of Public Health and Primary Care, Ghent University; Stefan Schreck, Adviser for Stakeholder Relations, DG SANTE, European Commission
Moderator: Elizabeth Kuiper, Head of Social Europe and Well-being programme, European Policy Centre
Healthcare systems across the EU have long sought to create as much value as possible from their available resources. The impact of the COVID-19 pandemic, combined with an ageing population and predicted increases in chronic disease, has intensified the need for efficient and sustainable patient-centric healthcare systems.
If no further action is taken, the number of people newly diagnosed with cancer every year in Europe will increase from the current 3.5 million to more than 4.3 million by 2035.What role can patient-reported outcomes (PROs) play in the shift towards value-based cancer care? What actions must member states take to create value-based healthcare systems? What role can Europe’s Beating Cancer Plan play in this endeavour? How can the EU best support member states’ transition towards value-based healthcare in not only oncology but also more broadly?
This CHES Policy Dialogue reflected on these questions and assessed the benefits of harnessing PROs to ensure high-quality cancer care for patients across the EU.
Speakers: Adela Maghear, Senior EU Affairs Officer, European Cancer Patient Coalition; Christina R. Åkerman, Chair of The 5612 Group AB; Senior Institute Associate at the Institute for Strategy and Competitiveness, Harvard Business School; Claire Chabloz, Medical Director, Johnson & Johnson Medical Devices France; Giovanni Gorgoni, Chair, European Regional and Local Health Authorities; Hans Martens, Senior Adviser, European Policy Centre; Jan De Maeseneer, Professor, Department of Public Health and Primary Care, Ghent University; Stefan Schreck, Adviser for Stakeholder Relations, DG SANTE, European Commission
Moderator: Elizabeth Kuiper, Head of Social Europe and Well-being programme, European Policy Centre
Healthcare systems across the EU have long sought to create as much value as possible from their available resources. The impact of the COVID-19 pandemic, combined with an ageing population and predicted increases in chronic disease, has intensified the need for efficient and sustainable patient-centric healthcare systems.
If no further action is taken, the number of people newly diagnosed with cancer every year in Europe will increase from the current 3.5 million to more than 4.3 million by 2035.What role can patient-reported outcomes (PROs) play in the shift towards value-based cancer care? What actions must member states take to create value-based healthcare systems? What role can Europe’s Beating Cancer Plan play in this endeavour? How can the EU best support member states’ transition towards value-based healthcare in not only oncology but also more broadly?
This CHES Policy Dialogue reflected on these questions and assessed the benefits of harnessing PROs to ensure high-quality cancer care for patients across the EU.
